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Rhabdomyosarcoma (RMS) affects the female reproductive tract and is one of the most common soft tissue sarcomas in 
childhood.1 Sarcoma botryoides or botyroid RMSs 
are a polypoid variant of embryonal RMS, arising 
from embryonal rhabdomyoblasts and constituting 
approximately 3% of all RMSs.1 The primary site 
of these tumours is closely related to the age of the 
patient; it is found in the vagina during infancy 
and early childhood, in the cervix during the 
active reproductive stage and in the corpus uteri for 
postmenopausal patients.2 Although vaginal tumours 
are five times more common than the cervical type, 
the latter appears to have a better prognosis than 
the former.3 
Botryoid RMS has a marked tendency for 
local recurrence after excision, often invading the 
adjacent organs.4 The management of this tumour is 
challenging as it presents at a younger age; at this age, 
the preservation of hormonal, sexual and reproductive 
function is essential. There are many methods 
of surgical approach and variations in adjuvant 
therapy in the management of these tumours. Over 
the past few decades, there has been a dramatic 
change in management strategy, from radical and 
often mutilating exenterative surgeries to a more 
conservative approach with adjuvant chemotherapy.1 
This report describes the management of a young girl 
with botryoid RMS of the cervix.
Case Report 
In August 2007, a 14-year-old female was referred to 
Kasturba Hospital, a university hospital in Manipal, 
India, for treatment and management of botryoid RMS 
of the cervix. She presented with a mass protruding 
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سرطان العضالت احملززة العنقودي يف عنق الرحم
تقرير حالة ومراجعة األدبيات
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abstract: Botryoid rhabdomyosarcoma is an aggressive malignancy that arises from embryonal rhabdomyo-
blasts. It is commonly seen in the genital tract of female infants and young children. Due to the young age of affected 
patients, this malignancy poses a management challenge as the preservation of hormonal, sexual and reproductive 
function is essential. There is currently no consensus regarding management. However, treatment strategies for 
these tumours have evolved from radical exenterative surgeries to more conservative management options. We 
report a case of botryoid rhabdomyosarcoma in an adolescent girl presenting to Kasturba Hospital, in Manipal, 
India, in August 2007 with botryoid rhabdomyosarcoma of the cervix. She was treated with surgery and adjuvant 
chemotherapy. The patient remained healthy until eight months after the surgery. After acquiring a varicella zoster 
virus infection, she died due to septic shock and multiple organ failure. Awareness of such an uncommon lesion and 
its clinical implications is important to avoid misdiagnosis. 
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مايتم  غالبا  الجنينية.  الع�سلية  الأرومة  من  تن�ساأ  والتي  ال�رس�سة  ال�رسطانات  من  العنقودي  املحززة  الع�سالت  �رسطان  يعترب  امللخ�ص: 
ت�سخي�س هذا الورم يف الر�سع والفتيات �سغار ال�سن.  ميثل عالج هذا الورم حتديا كبريا وذلك للحفاظ على الوظائف التنا�سلية واجلن�سية 
الأمثل لهذا املر�س. وبالرغم من ذلك فقد تطورت  العالج  اإجماع على  الآن  ال�سن. ول يوجد حتى  والهرمونية يف هوؤلء املر�سى �سغار 
ا�سرتاتيجيات العالج من اجتثاث الأح�ساء اجلذري اإىل اختيارات اأخرى اأكرث حتفظا. هذا تقرير حالة ل�رسطان الع�سالت املحززة العنقودي 
يف فتاة مراهقة ح�رست مل�ست�سفى كا�ستوربا مبانيبال، الهند يف اأغ�سط�س 2007 م�سابه ب�رسطان الع�سالت املحززة العنقودي يف عنق 
الرحم. مت عالج هذه الفتاة باجلراحة والعالج الكيميائي امل�ساعد. وقد ظلت الفتاة يف حالة �سحية جيدة ملدة 8 اأ�سهر عندما اأ�سيبت بعدوى 
فريو�س احلماق النطاقي ثم توفيت ب�سبب �سدمة اإنتانية مع ف�سل العديد من اأجهزة اجل�سم. من املهم زيادة الوعي بهذه الأورام غري الشائعة 
واآثارها ال�رسيرية لتجنب الت�سخي�س اخلاطئ.
مفتاح الكلمات: عنق الرحم؛ �رسطان الع�سالت؛ اجلراحه؛ العالج الكيميائي الإ�سعاعي؛ تقرير حالة؛ الهند.
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adequate margins along with the grape-like polypoidal 
yellowish-red cervix growth of 4–5 cm [Figure 1].
Postoperative histopathology revealed botryoid 
RMS of the cervix with no residual disease. All 
margins were free of tumours. Microscopy revealed 
a columnar and squamous epithelium overlying a 
malignant neoplasm [Figure 2]. The rhabdomyoblasts 
(strap cells) were visible [Figure 3]. No malignant cells 
were seen via peritoneal cytology. 
The patient was classified as category 1A accor-
ding to the staging classification criteria of the 
Intergroup Rhabdomyosarcoma Study Group (IRSG).5 
She received six cycles of postoperative adjuvant 
chemotherapy consisting of vincristine, actinomycin 
and cyclophosphamide (VAC) with the following 
regimen: 1.8 mg of vincristine weekly (at 1.5 mg/m2) 
and 0.5 mg of dactinomycin (at 0.015 mg/kg/day), 
1,200 mg of cyclophosphamide (at 1 mg/m2) and 200 mg 
of mesna at zero, four and eight hours, respectively, 
every 21 days. The patient had episodes of neutropaenia 
which delayed the above treatment regimen on several 
occasions during the chemotherapy course.
from the introitus which had been present for the 
previous six months and was particularly noticeable 
during menstruation. The patient also complained of 
a white discharge that was occasionally blood-stained. 
She did not have any significant medical or surgical 
history. General and systemic examinations were 
unremarkable. Upon local examination of the vulva, 
the mass was not apparent. However, on straining in 
a squatting position, a fleshy grape-like mass could be 
seen protruding from the vagina. It appeared reddish, 
friable and bled to the touch. An examination under 
anaesthesia revealed a reddish, smooth, glistening, 
polypoidal mass connected to the cervix by a thin 
pedicle. The fornices and both parametria were free 
of tumours.
A histopathological slide review performed 
at Kasturba Hospital confirmed the diagnosis of 
botryoid RMS. A metastatic work-up, including 
magnetic resonance imaging of the pelvis, computed 
tomography of the thorax and a bone scan, revealed 
that the disease was confined to the lower cervix. 
All routine preoperative laboratory parameters 
were normal. 
Unfortunately, detailed descriptions pertaining 
to surgical interventions and histopathological 
prognostic factors of RMS cases were not available 
for many previously published case reports. Due to 
the limited data available in the literature regarding 
the outcome of patients managed conservatively, 
clinicians counselled the patient’s parents about 
the condition and presented various management 
options. The parents opted for their daughter to 
undergo a hysterectomy. In August 2007, the patient 
underwent a type B1 radical hysterectomy under 
general anaesthesia. Intraoperatively, no lymph 
nodes were palpable and the upper abdomen was 
tumour-free with the botryoid RMS confined to the 
cervix. The uterus and cervix were removed with 
 
Figure 1: Hysterectomy specimen taken from an 
adolescent girl with botryoid rhabdomyosarcoma 
showing the grape-like polypoidal yellowish-red lesion 
connected to the cervix by a thin pedicle. The lesion was 
4–5 cm in size.
 
Figure 2: Haematoxylin and eosin histopathology 
stain demonstrating a prominent cambium layer 
overlying a malignant botryoid rhabdomyosarcoma at 
x10 magnification.
 
Figure 3: Haematoxylin and eosin histopathology stain 
showing the periglandular infiltration of the botryoid 
rhabdomyosarcoma tumour cells (rhabdomyoblasts or 
strap cells) at x10 magnification.
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The patient was followed-up regularly. She appeared 
to be healthy until approximately eight months after 
surgery, when she acquired a varicella zoster virus 
infection while undergoing chemotherapy. This later 
progressed to pneumonia and septicaemia. She was 
transferred to an intensive care unit where she died 
due to septic shock and multiple organ failure.
Discussion
Botryoid RMS is a rapidly growing rare malignancy 
seen in infants and young children.1 Although more 
than 100 nomenclatures exist for this tumour, the 
term ‘sarcoma botryoides’ was first used by Pfannen-
stiel in 1892.6 The appearance of the botryoid RMS 
results when the tumour arises under the mucosal 
surface of the organs, which forces the growth to 
assume a typical grape-like structure. A distinct 
cambium layer beneath the epithelium is characteristic 
of botryoid RMS.7 The patient reported here satisfied 
all three criteria essential for the botryoid variety of 
RMS (i.e. a polypoid appearance, an origin below a 
mucous membrane-covered surface and the presence 
of a cambium layer).8 In order to avoid misdiagnosis 
and mismanagement, it is essential for clinicians to 
know of this uncommon disease, particularly common 
sites and the aggressive nature and clinical implications 
of the tumour.
The currently reported patient presented with a 
mass in the vagina, which is among the most common 
presenting complaints for those with RMS.3 However, 
young children may present with vaginal bleeding or 
urinary or bowel symptoms.3 Since the occurrence 
of benign polyps in the vagina or cervix is extremely 
rare in childhood, the authors recommend that any 
polypoidal mass found in a child be regarded as 
botryoid RMS unless proven otherwise.
Only a few case series and reports regarding the 
management of botryoid RMS of the female genital 
tract are currently available in the literature. Due to 
the rare occurrence of these tumours, there is limited 
literature on the evaluation of optimal therapy and a 
lack of level 1 evidence. Hence, there is no uniform 
consensus in the management approach to these 
tumours. Over the decades, there has been a paradigm 
shift in management strategies for botryoid RMSs. 
Although ultra-radical surgery like pelvic exenteration 
was considered the treatment of choice in the late 
1960s, outcomes were often unsatisfactory. In the 
1970s, limited surgery with adjuvant chemotherapy 
and/or irradiation showed improved survival. 
Surgical aggressiveness gradually reduced from 
mutilating exenterative procedures to simple local 
excisions.9 The spectrum of surgical therapy now 
includes radical hysterectomies with or without 
lymphadenectomies,2,3,7,10–14 hysterectomies,3,15,16 vagi-
nectomies,16 cervicectomies,3 polypectomies,9,17–19 
local excisions,10,11,20 and diathermy loop excisions.9 
Botryoid RMSs are mostly either treated with 
surgery alone or with adjuvant chemotherapy 
and/or radiotherapy.21
Even with adjuvant chemotherapy regimens, there 
is no uniform agreement in the management of these 
tumours. Most investigators have used a combination 
of two or three chemotherapeutic agents.22,23 The 
most widely used chemotherapy regimen is VAC,11 
which was also used in the current case. VAC is the 
current gold-standard chemotherapy treatment. Phase 
II trials from Europe and the USA have shown that 
ifosfamide, as a single agent, is an active drug against 
RMS. In combination with other drugs, the response 
rate is even better. Irinotecan (a topoisomerase I 
inhibitor) also appears to have promising activity 
against RMS, with minimal haematopoietic toxicity.21 
There are variations in the type, dose and number of 
chemotherapy agents used. The number of cycles and 
the sequence of chemotherapy also differ.10,18 There 
are even reports of neoadjuvant chemotherapy being 
used to shrink large tumours before operations.11,16 
Although in earlier reports radiotherapy was used as 
a treatment modality, it has since been abandoned as 
it is now generally agreed that these tumours are not 
radiosensitive and this therapy would interfere with 
ovarian function and cause pelvic contractions. It is 
hence generally reserved only for residual tumours.23 
Copeland et al. conducted one of the largest case 
series on botryoid RMS of the female genital tract 
(n = 14) which showcased the evolution of treatment 
over a 30-year period.24 The second largest series 
was carried out by Daya et al. who were the first 
to demonstrate a conservative approach in the 
management of these tumours with a favourable 
outcome.3 Another series showed a successful outcome 
in 12 out of 14 cases treated via local excision followed 
by multidrug chemotherapy.11 However, two patients 
in this series required radical hysterectomies to control 
the disease.11 other reports have also shown favourable 
outcomes for cervical botryoid RMS patients who 
were treated via local resection and chemotherapy, 
with preservation of fertility.9,17,18,20
The progression to less extensive therapy over 
recent years is partly due to the response of this 
neoplasm to the VAC chemotherapy regimen.24 It 
should be emphasised that successful therapy with 
limited surgery is applicable only for patients who fall 
into IRSG categories 1 or 2.24 It is unknown whether 
localised well-differentiated lesions can be safely 
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of the infection. The infection may be presumed to 
be due to the transient altered immunological status 
of the patient while undergoing chemotherapy and 
exposure to varicella infection in a prevalent area; 
Karnataka in South India is a high prevalence area for 
varicella infections, especially in adolescents.27 Eight 
deaths have been similarly documented as a result of 
infection during management of genitourinary RMS 
in patients who received chemotherapy.5 Therefore, 
due to the limited literature on this issue, an evaluation 
of infective morbidity and mortality rates during 
chemotherapy treatment would be of great value for 
future reports. However, due to the rarity of these 
tumours, it may not be feasible to conduct randomised 
controlled trials to demonstrate the most appropriate 
treatment approach.
Conclusion
RMS of the female genital tract is a rapidly growing 
rare malignancy seen in infants and young children. 
The most effective treatment for this tumour has still 
not been well established and is a subject of on-going 
investigation. Due to the lack of data pertaining to 
surgical interventions and histopathological prog- 
nostic factors of RMS cases, in addition to the 
diversity in management approaches, it is difficult to 
draw absolute conclusions regarding overall treatment 
outcomes. However, there has been an increasing 
tendency towards conservative therapy in recent years. 
From the available literature, it appears that limited 
surgery with adjuvant multi-agent chemotherapy 
is feasible in the treatment of early cervical RMS in 
young patients.
References
1. Bell J, Averette H, Davis J, Toledano S. Genital rhabdomyo-
sarcoma: Current management and review of the literature. 
Obstet Gynecol Surv 1986; 41:257–63. doi: 10.1097/00006254-
198605000-00001.
2. Atlante M, Dionisi B, Cioni M, Di Ruzza D, Sedati P, Mariani L. 
Sarcoma botryoides of the uterine cervix in a young woman: A 
case report. Eur J Gynaecol Oncol 2000; 21:504–6.
3. Daya DA, Scully RE. Sarcoma botryoides of the uterine cervix in 
young women: A clinicopathological study of 13 cases. Gynecol 
Oncol 1988; 29:290–304. doi: 10.1016/0090-8258(88)90228-4.
4. Cywes S, Louw JH. Sarcoma botryoides of the vagina: A report 
of two cases. S Afr Med J 1961; 35:911–17. 
5. Ind T, Shepherd J. Pelvic tumours in adolescence. Best Pract 
Res Clin Obstet Gynaecol 2003; 17:149–68. doi: 10.1053/
ybeog.2002.0345.
6. Pfannenstiel J. Das traubige sarkom der cervix uteri. Virchows 
Arch Path Anat 1892; 127:305–37.
7. Mousavi A, Akhavan S. Sarcoma botryoides (embryonal 
rhabdomyosarcoma) of the uterine cervix in sisters. J Gynecol 
Oncol 2010; 21:273–5. doi: 10.3802/jgo.2010.21.4.273.
treated with conservative surgery alone without the 
use of adjuvant therapy. Daya et al. reported favourable 
outcomes in four young patients with cervical botryoid 
RMSs who were treated only by polypectomy or 
cervicectomy without chemotherapy.3 However, fatal 
recurrence with poor outcomes have been reported 
with the use of conservative surgery alone.24 Therefore, 
postoperative chemotherapy should be administered 
even for IRSG category 1 patients with cervical botryoid 
RMS, regardless of the type of surgical intervention 
performed. Unfortunately, the optimal number of 
adjuvant chemotherapy cycles needed is unknown.
The role of histopathology in the prognosis of RMS 
cannot be underestimated. Although three varieties of 
RMS have been described (embryonal, alveolar and 
undifferentiated), the embryonal type is the most 
common and has a favourable prognosis, whereas 
the alveolar type is rare with a poorer prognosis.8 
Embryonal RMS of the cervix must be distinguished 
pathologically from adenosarcomas with heterologous 
elements, malignant mixed Müllerian tumours 
and low-grade stromal sarcomas as the optimal 
management strategies and clinical outcomes differ 
for each.11 The tumour site, deep myometrial invasion,3 
and lymphatic invasion are important prognostic 
factors. Cervical RMSs have a better prognosis than 
similar tumours arising from other sites of the female 
genital tract.9 
The survival rates for vaginal and cervical lesions 
are 60% and 96% respectively.20 Overall survival has 
been reported as 79% in patients treated with surgery 
and adjuvant chemotherapy.25,26 Although some 
patients may be cured by simple surgical procedures, 
the risk of recurrence and metastatic spread remains 
a concern.1 The pelvis is the most common site of 
primary recurrence and the recurrence of this disease 
is rarely cured after definitive initial therapy.24 There 
are reports of extensive metastasis to the lung with 
high mortality, despite surgery and chemotherapy.1 
Cervical botryoid RMSs invade and recur despite 
adjuvant chemotherapy,9,11 and patients have died due 
to the recurrent disease.3
In the current case, the patient died due to sepsis 
during the follow-up period. Her death was not due 
to persistence or recurrence of the botyroid RMS. 
There was no evidence of residual disease and no deep 
infiltration to the myometrium. Therefore, there was 
a good chance of prolonged survival had the patient 
not contracted the varicella infection. Moreover, in 
retrospect, she would have been an ideal candidate 
for a conservative surgical approach. The patient 
acquired the varicella infection while undergoing 
chemotherapy; however, it is difficult to determine 
whether the chemotherapy was the causative agent 
Bajpai Neha, Attibele P. Manjunath, Shivarudraiah Girija and Kumar Pratap
Online Case Report | e437
8. Wenig BM. Undifferentiated malignant neoplasms of the 
sinonasal tract. Arch Pathol Lab Med 2009; 133: 699–712. 
doi: 10.1043/1543-2165-133.5.699.
9. Zanetta G, Rota SM, Lissoni A, Chiari S, Bratina G, Mangioni C. 
Conservative treatment followed by chemotherapy with 
doxorubicin and ifosfamide for cervical sarcoma botryoides 
in young females. Br J Cancer 1999; 80:403–6. doi: 10.1038/
sj.bjc.6690370.
10. Behtash N, Mousavi A, Tehranian A, Khanafshar N, Hanjani P. 
Embryonal rhabdomyosarcoma of the uterine cervix: Case 
report and review of the literature. Gynecol Oncol 2003; 
91:452–5. doi: 10.1016/S0090-8258(03)00539-0.
11. Dehner LP, Jarzembowski JA, Hill DA. Embryonal 
rhabdomyosarcoma of the uterine cervix: A report of 14 cases 
and a discussion of its unusual clinicopathological associations. 
Mod Pathol 2012; 25:602–14. doi: 10.1038/modpathol.2011.185.
12. Golbang P, Khan A, Scurry J, MacIsaac I, Planner R. Cervical 
sarcoma botryoides and ovarian Sertoli-Leydig cell tumor. 
Gynecol Oncol 1997; 67:102–6. doi: 10.1006/gyno.1997.4807.
13. Qiang JX, Takahashi O, Hatazawa J, Karube A, Ohyama N, 
Sato H, et al. Sarcoma botryoides of the uterine cervix: A case 
report. J Obstet Gynaecol Res 1998; 24:197–201. doi: 10.1111/
j.1447-0756.1998.tb00075.x.
14. Scaravilli G, Simeone S, Dell’Aversana Orabona G, Capuano S, 
Serao M, Rossi R, et al. Case report of a sarcoma botryoides of the 
uterine cervix in fertile age and literature review. Arch Gynecol 
Obstet 2009; 280:863–6. doi: 10.1007/s00404-009-1022-3.
15. Miyamoto T, Shiozawa T, Nakamura T, Konishi I. Sarcoma 
botryoides of the uterine cervix in a 46-year-old woman: Case 
report and literature review. Int J Gynecol Pathol 2004; 23:78–82. 
doi: 10.1097/01.pgp.0000101147.41312.54.
16. Deligeoroglou E, Tsimaris P, Creatsa M, Athanasopoulos N, 
Creatsas G. Application of Creatsas vaginoplasty after radical 
surgical treatment of sarcoma botryoides. J Pediatr Adolesc 
Gynecol 2014; 27:93–5. doi: 10.1016/j.jpag.2013.12.004.
17. Gordon AN, Montag TW. Sarcoma botryoides of the cervix: 
Excision followed by adjuvant chemotherapy for preservation 
of reproductive function. Gynecol Oncol 1990; 36:119–24. 
doi: 10.1016/0090-8258(90)90121-Z.
18. Bernal KL, Fahmy L, Remmenga S, Bridge J, Baker J. Embryonal 
rhabdomyosarcoma (sarcoma botryoides) of the cervix 
presenting as a cervical polyp treated with fertility-sparing 
surgery and adjuvant chemotherapy. Gynecol Oncol 2004; 
95:243–6. doi: 10.1016/j.ygyno.2004.06.049.
19. Rosenberg P, Carinelli S, Peiretti M, Zanagnolo V, Maggioni A. 
Cervical sarcoma botryoides and ovarian Sertoli-Leydig cell 
tumor: A case report and review of literature. Arch Gynecol 
Obstet 2012; 285:845–8. doi: 10.1007/s00404-011-2017-4.
20. Gruessner SE, Omwandho CO, Dreyer T, Blütters-Sawatzki R, 
Reiter A, Tinneberg HR, et al. Management of stage I cervical 
sarcoma botryoides in childhood and adolescence. Eur J Pediatr 
2004; 163:452–6. doi: 10.1007/s00431-004-1469-y.
21. Agarwala S. Pediatric rhabdomyosarcomas and nonrhabdo-
myosarcoma soft tissue sarcoma. J Indian Assoc Pediatr Surg 
2006; 11:15–23. doi: 10.4103/0971-9261.24632.
22. Arndt CA, Donaldson SS, Anderson JR, Andrassy RJ, 
Laurie F, Link MP, et al. What constitutes optimal therapy for 
patients with rhabdomyosarcoma of the female genital tract? 
Cancer 2001; 12:2454–68. doi: 10.1002/1097-0142(20010615)91 
:12<2454::AID-CNCR1281>3.0.CO;2-C.
23. Dayyabu AL, Adogu IO, Makama BS. Sarcoma botryoides, a 
management dilemma: A review of two cases. Int J Case Rep 
Imag 2014; 5:15–20. doi: 10.5348/ijcri-201458-CS-10044.
24. Copeland LJ, Gershenson DM, Saul PB, Sneige N, Stringer CA, 
Edwards CL. Sarcoma botryoides of the female genital tract. 
Obstet Gynecol 1985; 66:262–6.
25. Montag TW, D’ablaing G, Schlaerth, JB, Gaddis O Jr, 
Morrow CP. Embryonal rhabdomyosarcoma of the uterine 
corpus and cervix. Gynecol Oncol 1986; 25:171–94. 
doi: 10.1016/0090-8258(86)90098-3.
26. Brand E, Berek JS, Nieberg RK, Hacker NF. Rhabdomyosarcoma 
of the uterine cervix: Sarcoma botryoides. Cancer 1987; 60:1552–
60. doi: 10.1002/1097-0142(19871001)60:7<1552::AID-CNCR2 
820600724>3.0.CO;2-W.
27. Girish PN, Shetty NJ, Shetty VH, Vaz GF. Study of the clinical 
patterns in varicella in a tertiary hospital at coastal Karnataka. 
Online J Health Allied Sci 2011; 10:6.
